AlphAIAlphAI — Financial news for AI agents
investing.comOCT 232 min read$EVAX

Evaxion reports three-year data for cancer vaccine EVX-01

Evaxion A/S (EVAX) reported three-year phase 2 trial data for its cancer vaccine EVX-01, showing sustained immune response and no tumor progression in advanced melanoma patients. The data will be presented at the ESMO Congress 2026. EVX-01 is personalized and designed using Evaxion's AI-Immunology platform. The company has a cash runway into mid-2027.

Original reporting
investing.com
Published Oct 23, 2026, 6:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 6:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$EVAX
Bullish
high confidence
Mentioned
$EVAX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$EVAXBullishMed
01

Why it matters

The data shows a robust immune response and no tumor progression, which could accelerate partner interest and valuation.

02

Market read

Positive trial data is a catalyst for EVAX and may influence related AI‑immunology stocks.

03

What to watch

Cash runway into H2 2027 limits near‑term financing flexibility; upcoming regulatory scrutiny could affect timeline.

Relevance 8/10Novelty 8/10Timing: today

Background

The article reports Evaxion's first public disclosure of three‑year Phase 2 results for its EVX‑01 melanoma vaccine, presented at a major oncology congress.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

Evaxion disclosed three-year Phase 2 data showing 100% immune response and sustained clinical response in advanced melanoma patients.

Expected impact

upward pressure as the market prices in the encouraging efficacy results.

Evidence & confidence

Phase 2 data is a material clinical milestone; no prior public release of these three‑year results.

Market effects

Sector

May lift sentiment for personalized cancer‑vaccine and AI‑driven biotech peers.

Regional

European biotech markets could see modest gains.

Global

Adds to broader interest in AI‑enabled immunotherapy platforms.

Counterpoint

What could challenge this read

Investors may question durability of response beyond three years and await Phase 3 data before committing.

Key entities

  • company
    Evaxion A/S

    Danish biotech developing personalized cancer vaccines.

  • company
    MSD

    Manufacturer of pembrolizumab, used in combination with EVX‑01.

Read at source← All news

StoryEvaxion reports three-year durability and immune data for melanoma vaccine

Also covered by

1 outlet

Related articles

OCT 23
$EVAXMedAI 9/10

Six melanoma responders received Evaxion's vaccine alone in year three. None had tumor progression.

Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All six patients in the trial's extension showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 induced an immune response in all patients, with 89% of vaccine neoantigens generating potent T-cell responses.

stocktitan.net2 min
OCT 19
$EVAXHighAI 8/10

Evaxion stock surges on 3-year melanoma vaccine trial data

Evaxion AS ADR (EVAX) shares rose 21.6% after reporting 3-year data from its EVX-01 phase 2 trial in advanced melanoma patients. All patients maintained clinical responses with no tumor progression. The data will be presented at ESMO Congress 2026. EVX-01 is a personalized cancer vaccine developed using AI-Immunology platform.

investing.com2 min
OCT 19
$EVAXMedAI 8/10

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported sustained clinical responses for all patients at three-year follow-up in a phase 2 trial for its personalized cancer vaccine EVX-01 in advanced melanoma. The data, to be presented at ESMO 2026, showed a 75% objective response rate with 25% of patients achieving complete response. EVX-01 will be discussed in a webinar and poster session.

finanznachrichten.de2 min
OCT 19
$EVAXMedAI 8/10

Evaxion Reports Durable Three-Year Responses With EVX-01 In Advanced Melanoma

Evaxion A/S reported that patients in a Phase 2 study of its personalized cancer vaccine EVX-01 for advanced melanoma maintained responses for three years, with no tumor progression. The company will present the data at ESMO 2026, showing a 75% response rate and 92% clinical benefit at two years. EVX-01 is currently in development for advanced solid tumors. EVAX stock closed at $2.83 on October 16, 2026, and is up 2.83% in pre-market trading.

rttnews.com2 min